The Liver INSPECTR Trial: Towards improved understanding of liver function following radiotherapy

Abstract

Liver stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for primary liver cancer and liver metastases. Liver SABR can provide high rates of local control however tumour doses are limited by dose to surrounding organs at risk including liver and gastrointestinal structures. Dose limits to liver are based on anatomical liver, without understanding of underlying liver function. This report describes a prospective clinical trial which measures the spatial variance of liver function through Tc-99m Mebrofenin SPECT in the context of liver SABR.